West Pharmaceutical Services, Inc. (NYSE:WST) shares are surging Thursday after the injectable pharmaceutical packaging and delivery systems company delivered a robust beat on its second-quarter 2025 earnings and revenue, while also significantly raising its full-year guidance.
The strong performance was largely driven by exceptional growth in its High-Value Product (HVP) segment, particularly due to strong demand for GLP-1 elastomer products and ongoing momentum in HVP conversions.
